ASBP

Aspire Biopharma Holdings, Inc. Common Stock

ASBP

Market cap $22.3M

Overview Fund Activity

0.4500 USD

+0.0047

1.06%

At close Updated Sep 17, 2:39 PM EDT

1 day

1.06%

5 days

2.27%

1 month

-23.73%

3 months

39.62%

6 months

-29.35%

Year to date

-96.06%

1 year

-96.12%

5 years

-95.5%

10 years

-95.5%

About: Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1.01% more ownership

Funds ownership: 3.12% [Q1] → 4.13% (+1.01%) [Q2]

0% more funds holding

Funds holding: 15 [Q1] → 15 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

38% less capital invested

Capital invested by funds: $876K [Q1] → $545K (-$331K) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 4 articles about ASBP published over the past 30 days

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

BUZZ BOMB™ engages three specialized fitness influencers to grow the brand https://www.instagram.com/bobbymaximus/ https://www.instagram.com/midwest_kong/ https://www.instagram.com/ifbbpro_moose_the_stallion/ The influencers have hundreds of thousands of followers across social platforms BUZZ BOMB's™ influencers known for their authenticity and ability to create genuine connections with their followers in the fitness and health world Sublingual delivery of 50mg of caffeine to the user in less than two minutes BUZZ BOMB™ is available for purchase at buzzbomb.buzz , the Company's E-commerce website ESTERO, FL / ACCESS Newswire / September 17, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced it has launched its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ pre-workout product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed for immediate effect.

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity SupraNaturals is a leading private label manufacturer in the health and wellness industry BUZZ BOMB™ pre-workout: 50mg caffeine for energy and focus. Boosts performance potential.

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage Lab results showed Aspire's product acted approximately twice as fast as the current recommendation for chewed aspirin tablet treatment These clinical trial results enable a potential regulatory submission for accelerated approval on track for Q3 2025 ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced positive final results from its randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire's investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. The final results demonstrated that Aspire's sublingual aspirin product produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA, the active antiplatelet form of aspirin) compared to chewed aspirin tablets (p

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

According to the NIH , Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths Trial demonstrates dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets in clinical trial Aspire's sublingual aspirin was safe and well-tolerated Aspire plans to review clinical trial results with the FDA to enable a potential regulatory submission for accelerated approval ESTERO, FL / ACCESS Newswire / August 18, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced positive top-line data from its recent randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire's investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. Pharmacokinetics is the term that describes the four stages of absorption, distribution, metabolism, and excretion of drugs.

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, Interim Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 20 at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_5UneWjXKTOuzgbB4wpeByg One-on-One Meetings Aspire will also host virtual one-on-ones with investors on Wednesday, August 20 and Thursday, August 21, 2025.

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential 30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™'s four bold flavors As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake BUZZ BOMB™ is available for purchase at buzzbomb.buzz , the Company's new E-commerce website ESTERO, FL / ACCESS Newswire / August 13, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced the successful launch and distribution of over 30,000 BUZZ BOMB™ sample four-packs, its newsublingual pre-workout supplement, at FitCon and FitExpo, held August 1-3, in Salt Lake City and Anaheim, with an estimated combined attendance in excess of 70,000 people. BUZZ BOMB™, featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed.

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience ESTERO, FL / ACCESS Newswire / July 31, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced the rollout of its new e-commerce solution, buzzbomb.buzz with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Aspire platform and have them shipped directly to their door with access to exclusive promotions, and customer support.

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO ESTERO, FL / ACCESS Newswire / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced that the Company's Board of Directors (Board) has appointed Kraig Higginson as interim Chief Executive Officer (CEO), effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for four years.

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market ESTERO, FL / ACCESS Newswire / July 22, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced it plans to launch its newsublingual pre-workout supplement, BUZZ BOMB™, at FitCon and FitExpo, two of the largest fitness conventions held annually in Salt Lake City, Utah (August 1-2) and Anaheim, CA, (August 2-3), respectively. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential.

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Early positive consumer testimonials from initial Company product sampling Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout market Developed through over a decade of scientific research to deliver a patent-pending, fast-acting supplement formulation for maximum effect Completed initial production in four flavors Aspire to launch BUZZ BOMB™ at the FITCON and Fit Expo conventions in August ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / July 9, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced positive initial consumer feedback from the Company's sampling of its sublingual pre-workout supplement, BUZZ BOMB™. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential.

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

See News Rankings

Charts implemented using Lightweight Charts™